Loading...
Market
Next major partnership for CytomX post-CX-904 success by 2024?
5
Resolution / Starting Odds
Partnership with Pfizer • 25%
Partnership with Johnson & Johnson • 25%
Partnership with Merck • 25%
No new partnership • 25%
CytomX press releases or major financial news outlets
Story
CytomX CX-904 Shows Promise in Pancreatic Cancer, Achieves $10M Milestones
May 8, 2024, 08:36 PM
CytomX Therapeutics announced positive initial Phase 1a dose escalation data for its monotherapy CX-904, an EGFRxCD3 PROBODY T-cell engager. The study reported measurable tumor reductions in eight patients, including two of six efficacy-evaluable pancreatic cancer patients who achieved confirmed partial responses per RECIST 1.1. All six pancreatic cancer patients reached disease control. Despite this, the results in other cancers like CRC, NSCLC, gastric, and HNSCC were less promising, with only partial responses observed in pancreatic cancer. The company's stock experienced significant volatility, surging 83% after hours following the announcement. CytomX has partnered with Amgen and achieved $10 million of milestones under a T-cell engaging bispecific collaboration with Astellas for preclinical progress on the first two programs. Further updates are expected by the end of 2024.
View original story
Similar markets
No new partnerships • 33%
Partner with a major pharmaceutical company • 33%
Partner with multiple smaller pharmaceutical companies • 33%
None • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
Moderna forms new partnerships • 25%
Pfizer/BioNTech forms new partnerships • 25%
Both companies form new partnerships • 25%
No new partnerships formed • 25%
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
No collaboration • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Seek further regulatory approvals • 33%
Begin commercial production • 33%
Partner with another company for distribution • 34%